Effect of Mycophenolate Mofetil in combination with standard immunosuppression on chronic transplant nephropathy: 1 year experience

Khachatryan, Naira; Wauters, J.‐P.; Vogel, G

doi:10.1016/s0041-1345(01)02918-9

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This trial was mirrored by that of Ducloux et al [64] whose regimen of substituting MMF for Aza and withdrawing CyA in 31 patients with CAN demonstrated improved serum creatinine after conversion, which remained stable after a mean follow-up of 27 months [227 ± 31 lmol/L versus 185 ± 50 lmol/L (2.55 ± 0.35 versus 2.01 ± 0.56 mg/dL; P < 0.0005)]. However, they also reported a high incidence of infection (28% of patients) with the 2 g daily dosing regimen, an observation that was repeated by Khatchatryan et al [65], who found that it was difficult to exceed 1.5 g/day of MMF without troublesome side effects. This difficulty was also evident in the recently reported and elegantly designed "creeping creatinine study," where 144 subjects with CAN were randomized to two groups.…”

Section: Mmfmentioning

confidence: 79%

What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulations

Afzali

Taylor

Goldsmith

2005

Kidney International

View full text Add to dashboard Cite

Given the potency of modern immunosuppressive agents, kidney transplantation across alloantingen barriers is a routine phenomenon with excellent 1-year graft survival in most centers. However, the improvement in 1-year graft survival has not been matched by improvements in long-term graft function and chronic allograft nephropathy (CAN) remains the second commonest cause of graft attrition over time. Calcineurin inhibitors, namely cyclosporine A (CyA) and tacrolimus, have been implicated as causal agents in the development of the fibrotic processes that are the hallmarks of CAN. Many studies have, therefore, concentrated on the improvement of long term graft function through the modulation of immunosuppressive therapy. It is the purpose of this review to describe and appraise the available evidence for the prevention and management of CAN through modulation of immunosuppressive agents.

show abstract

Section: Mmfmentioning

confidence: 79%